New hope for stroke patients on blood thinners: Clot-Buster drug under trial
NCT ID NCT07092709
First seen Jan 08, 2026 · Last updated Jun 23, 2026 · Updated 22 times
Summary
This study is testing whether a drug called tenecteplase can help people who have had a stroke and recently took blood thinners (DOACs). The drug is given as a single injection to break up blood clots. About 912 participants will be randomly assigned to receive either tenecteplase or a placebo. The main goal is to see if more people recover with little or no disability 90 days after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tenecteplase (a clot-busting drug)
What this could lead to
If it works, this could provide a safe and effective way to treat stroke in patients who are currently on blood thinners, expanding treatment options.
What could go wrong
This is a Phase 3 trial, but it's still experimental. The drug may not improve outcomes or could increase bleeding risk, especially in this specific patient group.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.